Background/Aims: Previous studies have reported a possible relevance between proton pump inhibitor (PPI) use and 3 new gastric mucosal changes: black spots (BSs), white flat elevated mucosa (WFEM), and cobblestone-like mucosa (CLM). The aim of this study was to investigate the association between these mucosal changes and multiple factors including PPI use. Methods: All subjects who underwent a routine esophagogastroduodenoscopy (EGD) were successively enrolled. Endoscopists carried out the EGD after being blinded about ­information on patient PPI usage and determined the presence of these mucosal changes. The ratio of each factor was ­compared in cases with and without each gastric finding. Results: Out of 1,214 patients, BSs were recognized in 75 (6.2%) cases, WFEM in 59 (4.9%), and CLM in 41 (3.4%). In logistic regression analysis, PPI use was significantly correlated with all of these findings (BSs: OR 2.94; 95% CI 1.66–5.21), (WFEM: OR 3.58; 95% CI 1.94–6.61), and (CLM: OR 4.57; 95% CI 2.34–9.96), and Helicobacter pylori eradication was related to BSs (OR 3.01; 95% CI 1.73–5.24) and WFEM (OR 2.11; 95% CI 1.08–4.11). Decision-tree analyses showed that H. pylori eradication was associated with all findings. Conclusions: All of the considered findings were correlated with PPI and H. pylori eradication.

Journal Section:
Original Paper
Keywords:
Black spot, Cobblestone-like mucosa, Helicobacter pylori eradication, Proton pump inhibitor, White flat elevated mucosa
1.
Holt S, Howden CW: Omeprazole. Overview and opinion. Dig Dis Sci 1991; 36: 385–393.
[PubMed]
https://doi.org/10.1007/BF01298864
2.
Poynard T, Lemaire M, Agostini H: Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 1995; 7: 661–665.
[PubMed]
3.
Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ: Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study. Aliment Pharmacol Ther 1999; 13: 179–186.
[PubMed]
https://doi.org/10.1046/j.1365-2036.1999.00449.x
4.
Yeomans ND, Tulassay Z, Juhasz L, Racz I, Howard JM, van Rensburg CJ, et al: A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998; 338: 719–726.
[PubMed]
https://doi.org/10.1056/NEJM199803123381104
5.
Chiba N, De Gara CJ, Wilkinson JM, Hunt RH: Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798–1810.
[PubMed]
https://doi.org/10.1053/gast.1997.v112.pm9178669
6.
Kahrilas PJ, Howden CW, Hughes N: Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease. Am J Gastroenterol 2011; 106: 1419–1425;quiz 26.
[PubMed]
https://doi.org/10.1038/ajg.2011.146
7.
Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME: Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2013:CD002095.
[PubMed]
https://doi.org/10.1002/14651858.CD002095.pub5
8.
el-Zimaity HM, Jackson FW, Graham DY: Fundic gland polyps developing during omeprazole therapy. Am J Gastroenterol 1997; 92: 1858–1860.
[PubMed]
9.
Jalving M, Koornstra JJ, Wesseling J, Boezen HM, DE Jong S, Kleibeuker JH: Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther 2006; 24: 1341–1348.
[PubMed]
https://doi.org/10.1111/j.1365-2036.2006.03127.x
10.
Hongo M, Fujimoto K: Incidence and risk factor of fundic gland polyp and hyperplastic polyp in long-term proton pump inhibitor therapy: a prospective study in Japan. J Gastroenterol 2010; 45: 618–624.
[PubMed]
https://doi.org/10.1007/s00535-010-0207-7
11.
Hatano Y, Haruma K, Ayaki M, Kamada T, Ohtani H, Murao T, et al: Black spot, a novel gastric finding potentially induced by proton pump inhibitors. Intern Med 2016; 55: 3079–3084.
[PubMed]
https://doi.org/10.2169/internalmedicine.55.6974
12.
Haruma K, Kato M, Inoue K, Murakami K, Kamada T: Ien no Kyoto Bunrui [Kyoto Classification of Gastritis]. Tokyo, Nihon Medical Center Press, 2014, pp 91–93 (in Japanese).
13.
Kiso M, Ito M, Boda T, Kotachi T, Masuda K, Hata K, et al: Endoscopic findings of the gastric mucosa during long-term use of proton pump inhibitor – a multicenter study. Scand J Gastroenterol 2017; 52: 828–832.
[PubMed]
https://doi.org/10.1080/00365521.2017.1322137
14.
Miyamoto S, Kato M, Tsuda M, Matsuda K, Muranaka T, Abiko S, et al: Gastric mucosal cracked and cobblestone-like changes resulting from proton pump inhibitor use. Dig Endosc 2017; 29: 307–313.
[PubMed]
https://doi.org/10.1111/den.12765
15.
Takahari K, Haruma K, Ohtani H, Kiyoto S, Watanabe A, Kamada T, et al: Proton pump inhibitor induction of gastric cobblestone-like lesions in the stomach. Intern Med 2017; 56: 2699–2703.
[PubMed]
https://doi.org/10.2169/internalmedicine.7964-16
16.
Nakagawa M, Abe M, Takada S, Yamabe T, Kinugasa H, Miyahara K, et al: Endoscopic features of gastric adenocarcinoma of fundic gland type. Stomach Intestine 2015; 50: 1521–1531.
17.
Cats A, Schenk BE, Bloemena E, Roosedaal R, Lindeman J, Biemond I, et al: Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment. Hum Pathol 2000; 31: 684–690.
[PubMed]
https://doi.org/10.1053/hupa.2000.7637
18.
Stolte M, Bethke B, Ruhl G, Ritter M: Omeprazole-induced pseudohypertrophy of gastric parietal cells. Z Gastroenterol 1992; 30: 134–138.
[PubMed]
19.
Driman DK, Wright C, Tougas G, Riddell RH: Omeprazole produces parietal cell hypertrophy and hyperplasia in humans. Dig Dis Sci 1996; 41: 2039–2047.
[PubMed]
https://doi.org/10.1007/BF02093608
20.
Parfitt JR, Driman DK: Pathological effects of drugs on the gastrointestinal tract: a review. Hum Pathol 2007; 38: 527–536.
[PubMed]
https://doi.org/10.1016/j.humpath.2007.01.014
21.
Kawaguchi M: Tahatsusei hakushoku henpei ryuki [multiple white and flat elevated lesions]. Stomach Intestine 2017; 52: 610 [in Japanese].
22.
Adachi K, Mishiro T, Okada M, Kinoshita Y: Prevalence of multiple white and flat elevated lesions in individuals undergoing a medical checkup. Intern Med 2017 (Advance Publication by J-STAGE: December 27, 2017).
23.
Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al: Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982–992.
[PubMed]
https://doi.org/10.1053/j.ajkd.2008.12.034
24.
Kimura K, Takemoto T: An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 1969; 1: 87–97.
https://doi.org/10.1055/s-0028-1098086
25.
Krishnamurthy S, Dayal Y: Parietal cell protrusions in gastric ulcer disease. Hum Pathol 1997; 28: 1126–1130.
[PubMed]
https://doi.org/10.1016/S0046-8177(97)90249-5
26.
Synnerstad I, Holm L: Omeprazole induces high intraglandular pressure in the rat gastric mucosa. Gastroenterology 1997; 112: 1221–1230.
[PubMed]
https://doi.org/10.1016/S0016-5085(97)70134-3
27.
Oberhuber G, Stolte M: Gastric polyps: an update of their pathology and biological significance. Virchows Arch 2000; 437: 581–590.
[PubMed]
https://doi.org/10.1007/s00428-016-2011-0
28.
Ueyama H, Yao T, Nakashima Y, Hirakawa K, Oshiro Y, Hirahashi M, et al: Gastric adenocarcinoma of fundic gland type (chief cell predominant type): proposal for a new entity of gastric adenocarcinoma. Am J Surg Pathol 2010; 34: 609–619.
[PubMed]
https://doi.org/10.1097/PAS.0b013e3181d94d53
© 2018 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2018
You do not currently have access to this content.